Khoso Baluch - 26 Jul 2026 Form 4 Insider Report for Processa Pharmaceuticals, Inc. (PCSA)

Reporting relationship: Director
Issuer ticker: PCSA
Reported as of: 26 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 Jul 2026, 20:19:12 UTC
Prior SEC filing: 30 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Khoso Baluch by John J. Wolfel, as Attorney-in-Fact

Key filing fact

Khoso Baluch filed Form 4 for Processa Pharmaceuticals, Inc. (PCSA) on 28 Jul 2026.

Key facts

This page summarizes Khoso Baluch's Form 4 filing for Processa Pharmaceuticals, Inc. (PCSA).
1 reported transaction and 2 derivative rows are listed below.
Accepted by SEC: 28 Jul 2026, 20:19.

Change

Previous filing in this sequence was filed on 30 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001686223 Primary reporting owner

Baluch Khoso

Relationship: Director
Address: C/O PROCESSA PHARMACEUTICALS, INC., 601 21ST STREET SUITE 300, VERO BEACH
Signature: /s/ Khoso Baluch by John J. Wolfel, as Attorney-in-Fact
Signature date: 28 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCSA holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 2,528
Date: 26 Jul 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCSA transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +33,500
Change %: +638%
Price: $0.000000^*
Shares after: 38,749
Date: 26 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 33,500
Exercise price: $0.000000
Footnotes: F1, F3

PCSA holding Derivative

Stock Options (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 12,000
Date: 26 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 12,000
Exercise price: $4.96
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock. These RSUs vested upon grant, but will not be distributed until the earlier of: (i) their termination; (ii) six month anniversary of the grant date; (iii) change of control; or (iv) their death.

Footnote F2

Stock options vest one-third on the first anniversary date of the grant, with the remaining options vesting ratably over the subsequent two years.

Footnote F3

Reflects the 1-for-25 reverse stock split effected by the Issuer on December 17, 2025.